CN114773437B - Antibacterial peptide with broad-spectrum bactericidal activity and application thereof - Google Patents

Antibacterial peptide with broad-spectrum bactericidal activity and application thereof Download PDF

Info

Publication number
CN114773437B
CN114773437B CN202210392287.1A CN202210392287A CN114773437B CN 114773437 B CN114773437 B CN 114773437B CN 202210392287 A CN202210392287 A CN 202210392287A CN 114773437 B CN114773437 B CN 114773437B
Authority
CN
China
Prior art keywords
antibacterial
peptides
peptide
activity
broad
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210392287.1A
Other languages
Chinese (zh)
Other versions
CN114773437A (en
Inventor
国果
杨隆兵
张进
焦正龙
孙朝琴
彭建
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guizhou Medical University
Original Assignee
Guizhou Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guizhou Medical University filed Critical Guizhou Medical University
Priority to CN202410090896.0A priority Critical patent/CN117903254A/en
Priority to CN202410090897.5A priority patent/CN117886895A/en
Priority to CN202210392287.1A priority patent/CN114773437B/en
Publication of CN114773437A publication Critical patent/CN114773437A/en
Application granted granted Critical
Publication of CN114773437B publication Critical patent/CN114773437B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

An antibacterial peptide with broad-spectrum antibacterial activity, especially the antibacterial activity to cryptococcus neoformans, and features quick sterilization, less generation of drug resistance, high safety, no obvious cytotoxicity and high environmental stability.

Description

Antibacterial peptide with broad-spectrum bactericidal activity and application thereof
Technical Field
The invention relates to the technical field of biological medicines, in particular to an antibacterial peptide with broad-spectrum bactericidal activity and application thereof.
Background
Antibacterial peptides are a class of small molecule proteins with antibacterial activity. Since the first antimicrobial peptide cecropin was isolated from silkworm pupa by the swedish scientist Boman et al, more than 1000 antimicrobial peptides were found in a wide spectrum of organisms including insects, amphibians, aquatic animals, and mammals including humans, even plants and bacteria. Endogenous antibacterial peptide is synthesized in organism through induction, plays an important role in resisting pathogen invasion, and is an important component of organism nonspecific immunity.
The antibacterial activity of the antibacterial peptide has the characteristics of high selectivity, rapid sterilization, broad action spectrum and difficulty in forming resistance, so that the antibacterial peptide becomes an ideal candidate for researching and developing novel antibiotics. At present, the antibacterial peptide is expected to become a potential substitute of antibiotics due to the advantages of broad antibacterial spectrum, unique action mechanism, difficult generation of drug resistance and the like; in recent decades, the wide attention of researchers at home and abroad is drawn, and the antibacterial and bactericidal performance, drug resistance, safety, cytotoxicity and environmental stability of antibacterial peptides are important points of research at present.
Disclosure of Invention
In order to solve the defects and shortcomings in the prior art, the invention provides an antibacterial peptide with broad-spectrum bactericidal activity and application thereof.
The technical scheme adopted by the invention is as follows: an antimicrobial peptide having broad-spectrum bactericidal activity, comprising the antimicrobial peptides AMP-20, AMP-29, AMP-32, comprising or consisting of:
(a) SEQ ID NO:1 to 3; or;
(b) SEQ ID NO:1 to 3, and the sequence has an amino acid sequence having at least 80% sequence identity.
The spatial structures of the antimicrobial peptides AMP-20, AMP-29 and AMP-32 all show alpha-helix and beta-sheet structures, wherein the alpha-helix structure ratio is the largest.
The antimicrobial peptides AMP-20, AMP-29 and AMP-32 are alpha helical peptides
The antibacterial peptide is applied to the preparation of antibacterial drugs.
The antibacterial drug is a broad-spectrum antibacterial drug.
The antibacterial drug has antibacterial activity on cryptococcus neoformans, candida albicans, candida krusei, drug-resistant candida tropicalis, gram-negative escherichia coli and gram-positive staphylococcus aureus.
An application of the antibacterial peptide in preparing the antibacterial and bactericidal medicine for cryptococcus.
The minimum bactericidal concentration of the antibacterial peptide on cryptococcus is 2-16 mug/mL.
The beneficial effects of the invention are as follows: the invention provides an antibacterial peptide with broad-spectrum bactericidal activity and application thereof, which have the advantages of broad-spectrum antibacterial activity, especially strongest antibacterial activity on cryptococcus, rapid bactericidal property, difficult induction of drug resistance, higher safety, no obvious cytotoxicity and strong environmental stability.
Drawings
FIG. 1 is a model of the helical and three-dimensional structure prediction of the novel peptides AMP-20, AMP-29, AMP-32.
FIG. 2 shows time-sterilization curves for the novel peptides AMP-20, AMP-29, AMP-32 versus Cryptococcus H99.
FIG. 3 shows the induction of drug resistance by cryptococcus H99 at the concentration of the novel peptide Sub-MIC.
FIG. 4 shows the hemolysis of human erythrocytes by the novel peptides AMP-20, AMP-29, and AMP-32.
FIG. 5 shows cytotoxicity of the novel peptides AMP-20, AMP-29, AMP-32 against HK-2, hepG2, LO2, RAW 264.7.
Figure 6 shows the in vivo toxicity of H99 to larvae of cnaphalocrocis medinalis.
FIG. 7 is an in vivo treatment of neopeptides AMP-20, AMP-29, AMP-32 in a wax moth infection model; wherein 1X 10 is used 8 CFU/mL cryptococcus neoformans H99 infects larvae of cnaphalocrocis medinalis and is treated with 3 new peptides and fluconazole and amphotericin B, respectively. (A) Schematic time diagram of drug treatment of wax moth infection model. Toxicity of the drug to larvae. Survival of the larvae of each group after drug treatment. (D) 2 replicates were loaded with larvae (n=3), each replicate was sacrificed after 24h, homogenized and plated, and colonies were counted to determine CFU for each larvae. (E) Representative larval photographs in sky white control group 5 (PBS Only), model group (H99 Only), and drug treatment group (AMP-20, AMP-29, AMP-32, FLC, and AMB). The experiment was performed with a combination of 2 replicates (n=32) and for each replicate, the survival of a group of 16 larvae per treatment was monitored over 7 days.
Detailed Description
The following description of the embodiments of the present invention will be made clearly and completely with reference to the accompanying drawings, in which it is apparent that the embodiments described are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
5775 polypeptide sequences with antifungal activity are collected through the arrangement of a network database, a literature, a monograph and a patent, 5775 negative sequences with the same length distribution as those of the polypeptide and antibacterial activity are randomly extracted on a UniProt to serve as references, and a discrimination model is established for the antifungal polypeptide through a support vector machine. Our built antifungal webserver (http:// www.chemoinfolab.com/an validation) has achieved free open sharing of models, with 1000 accesses and 200 data submissions received over three months. The unknown polypeptide sequences with the length of 11-75 amino acids are searched from UniProt, 3445312 sequences are taken in total, the model is adopted to distinguish and screen whether the unknown functional sequences have antifungal activity, and a batch of polypeptide sequences with possible antifungal activity are determined by combining with the custom antifungal index (AFI). The solid phase synthesis technology is adopted to synthesize about 50 polypeptides, the antifungal activity of the polypeptides is verified in a laboratory, and finally 3 novel peptides AMP-20 (YFPPAKRLLNWAKKKVGIKKKKK), AMP-29 (EKKPWARLRFKFKLLKGLAKKMK) and AMP-32 (LKKLAGKIYRVLAKL) with broad-spectrum antibacterial activity and outstanding anti-cryptococcus activity are screened out of the polypeptides.
Example 1
Structural analysis of 3 novel peptides
The peptides Mm-AMP1, dv-AMP1, nc-AMP1 were analyzed for the distribution of hydrophilic and hydrophobic amino acids in the amino acid sequence, as well as for the average hydrophobicity and average hydrophobic moment, using NetWheels (http:// lbqp. Ub. Br/NetWheels /) online software. Meanwhile, the spatial structure (tertiary structure) of peptides AMP-20, AMP-29 and AMP-32 is simulated by using protein spatial structure simulation software I-TASSER (https:// zhanggroup. Org/I-TASSER /). As a result, as shown in FIG. 1, the polar amino acids and the nonpolar amino acids of AMP-20 were uniformly distributed, the average hydrophobicity was 0.129, and the average hydrophobic moment was 0.203. The polar amino acids and the nonpolar amino acids of AMP-29 are uniformly distributed, the average hydrophobicity is 0.201, and the average hydrophobic moment is 0.360.AMP-32 has relatively few polar amino acids, most of which are nonpolar amino acids, with an average hydrophobicity of 0.429 and an average hydrophobic moment of 0.738. The spatial structure of peptides AMP-20, AMP-29, AMP-32 shows that the spatial structure of 3 new peptides exhibits an alpha-helix and a beta-sheet structure, wherein the alpha-helix structure ratio is maximized, and 3 new peptides are alpha-helix peptides.
Example 2
The novel peptides have broad-spectrum antibacterial activity and outstanding anti-cryptococcus neoformans activity
To determine the drug sensitivity of 3 new peptides to bacteria and fungi, we used a micro-liquid dilution method to determine the Minimum Inhibitory Concentration (MIC) and minimum bactericidal concentration (MFC) values, respectively. The results showed that AMP-20, AMP-29, AMP-32 have MIC values of 4. Mu.g/mL, 4. Mu.g/mL and 2. Mu.g/mL for Cryptococcus neoformans H99 and KN99, respectively; MFC values were 4. Mu.g/mL, 8. Mu.g/mL and 2. Mu.g/mL. MIC for candida albicans, candida krusei and even drug-resistant candida tropicalis is 16-32 mug/mL, and besides the strong effect on fungi, the peptides have certain antibacterial activity on gram-negative bacteria escherichia coli (MIC 8-32 mug/mL) and gram-positive bacteria staphylococcus aureus (MIC 64-128 mug/mL). Laboratory results confirm that these several peptides are broad spectrum antimicrobial peptides, with the strongest antimicrobial activity against cryptococcus (table 1).
To further confirm the activity of the novel peptides on cryptococcus neoformans, we expanded the tested strains of cryptococcus neoformans, and continued determination of their MIC and MFC for the other 16 clinical strains, and as a result, still excited, the MIC values of the three peptides were 4-8. Mu.g/mL, 4-16. Mu.g/mL and 2-4. Mu.g/mL, respectively; MFC values were 4 to 8. Mu.g/mL, 8 to 16. Mu.g/mL, and 2 to 4. Mu.g/mL, respectively (Table 2). The antibacterial activity of the AMP-20 and the AMP-29 is equivalent to that of a clinically common antifungal drug, namely fluconazole and caspofungin, and is stronger than that of 5-fluorouracil; the AMP-32 activity was most prominent, and the anticoccidial effect was stronger than that of the above 3 antibiotics, thus confirming the prominent anticoccidial activity of the novel peptides.
TABLE 1 antibacterial Spectrometry of novel peptides AMP-20, AMP-29, AMP-32
Note that: "-" is indicated as not measured
TABLE 2 MIC and MFC values of novel peptides AMP-20, AMP-29, AMP-32 for Cryptococcus neoformans
Example 3
The new peptide can play a role in sterilization within 2h
The antibacterial peptide has antibacterial effect and bactericidal effect, and in order to determine whether the novel peptide has fungicidal effect, the time-bactericidal curve of the novel peptide on cryptococcus is measured. The results show that 3 novel peptides have bactericidal activity against cryptococcus neoformans H99 within 2H (FIG. 2), whereas fluconazole can only inhibit cryptococcus growth, and amphotericin can achieve bactericidal effect at 4H. The above results suggest that the novel peptides AMP-20, AMP-29, AMP-32 have a relatively rapid fungicidal activity against Cryptococcus neoformans.
Example 4
The new peptide is not easy to induce drug resistance
The difficulty in generating drug resistance is a special advantage of the antibacterial peptide. To determine whether the neopeptides were resistant, we induced resistance by repeated treatment of cryptococcus with submic concentrations of the neopeptides. As shown in FIG. 3, in the 10-generation MIC test, the sensitivity of 3 novel peptides to cryptococcus neoformans H99 remained relatively stable, and no drug resistance phenomenon occurred, suggesting that the novel peptides AMP-20, AMP-29 and AMP-32 are not easy to induce drug resistance.
Example 5
The novel peptide has high safety
To initially define the safety of 3 new peptides, we examined their hemolysis, cytotoxicity and serum stability. We incubated different concentrations of neopeptide with 2% final concentration of human erythrocytes for 1h, respectively, with 10mM PBS and 1% Triton-X100 as negative and positive controls. The results showed that none of the 3 peptides showed any evidence of human erythrocytes at a concentration of 64. Mu.g/mLApparent hemolysis, HC 50 The values were 202.96, 136.51 and 141.41. Mu.g/mL, respectively. Only when the peptide concentration is>At 64. Mu.g/mL, a slight hemolysis effect was seen (FIG. 4).
To clarify how do the novel peptides AMP-20, AMP-29, AMP-32 were cytotoxic? The cytotoxicity determination of the novel peptide is determined by using human kidney proximal tubular epithelial cells HK-2, human liver cancer cells HepG2, human normal liver cells LO2 and mouse macrophage RAW264.7 as test cells and adopting a CCK8 method. As shown in FIG. 5, 3 novel peptides showed no significant cytotoxicity to HK-2, hepG2, LO2 and RAW264.7 at 32. Mu.g/mL, IC 50 The values are shown in Table 3.
TABLE 3 IC of the novel peptides AMP-20, AMP-29, AMP-32 against HK-2, hepG2, LO2 and RAW264.7 cells 50 Value of
To initially evaluate the stability of the novel peptides in human serum and in different environments, the MIC changes of the novel peptides in different environments were determined using a micropluid dilution method. As a result, it was found that 10% human serum, 150mM NaCl and 4.5mM KCl had no effect on the activity of the novel peptide. Moreover, surprised by the human, the antibacterial activity of the novel peptide is obviously enhanced in the environment of 10% human serum, the MIC is changed from 2-4 to MIC <2, and it is presumed that the antibacterial peptide plays a role in immune protein in serum, so that the antibacterial activity of the antibacterial peptide is further enhanced. However, as with other polypeptides, the novel peptides were trypsin sensitive and susceptible to inactivation in a trypsin environment of 1mg/mL (Table 4).
TABLE 4 determination of stability of novel peptides in different environments
Example 6
The new peptide treatment can obviously reduce the death rate and fungal load of larvae infected by the Chilo suppressalis
In vitro we have confirmed that 3 new peptides all have strong anti-cryptococcus activity, but it is not known whether the antibacterial effect can be exerted in vivo. In order to preliminarily evaluate the in-vivo antibacterial effect of the novel peptide, the toxicity of the novel peptide to the larva of the Chilo suppressalis and the time-survival curve after the novel peptide infects the larva of the Chilo suppressalis H99 are measured firstly by taking the H99 of the novel peptide as an infectious strain, a larva of the Chilo suppressalis infection model is constructed on the basis, after intervention treatment by the novel peptide with different concentrations, the survival rate of each group of larva is recorded, and the fungal load of the larva is measured by a colony counting method.
The fumbling result of the infection concentration of Cryptococcus H99 larva with wax moth shows that the larva is injected 5X 10 8 All died within 48H after CFU/mL H99, 1.0X10 8 The CFU/mL group died all over 96 hours, whereas 0.5X10 8 The CFU/mL H99 group still had 10% larval survival after 168H (figure 6). Through looking through the related literature and combining the research results, 1.0X10 is selected 8 The CFU/mL group served as the infectious dose for the subsequent experiments.
After injection of different concentrations of neopeptide into larvae of Chilo suppressalis, neither AMP-20 nor AMP-29 showed significant toxicity to larvae in the range of 8-64 mg/kg, with 100% survival and 90% survival of larvae in the 64mg/kg AMP-32 group (FIG. 7-B). In the infection experiments, model larvae died 100% on day 4, while 3 peptides were effective in prolonging survival time of infected larvae, with more than 80% of larvae in the 32mg/kg group surviving to day 5 and more than 35% of larvae surviving to day 7 (FIGS. 7-C, 7-E). The results of the fungal load on the worms showed that the load on the worms was significantly reduced (P < 0.01) compared to the model group for all peptide treatment groups (fig. 7-D). The results indicate that 3 new peptides can play antibacterial activity in the bodies of infected larvae, the survival rate of the infected larvae can be obviously improved, and the bacterial load of the larvae can be reduced.
The skilled person will know: while the invention has been described in terms of the foregoing embodiments, the inventive concepts are not limited to the invention, and any modifications that use the inventive concepts are intended to be within the scope of the appended claims.
The above description is only a preferred embodiment of the present invention, and the protection scope of the present invention is not limited to the above examples, and all technical solutions belonging to the concept of the present invention belong to the protection scope of the present invention. It should be noted that modifications and adaptations to the present invention may occur to one skilled in the art without departing from the principles of the present invention and are intended to be within the scope of the present invention.
Sequence listing
<110> university of medical science in Guizhou
<120> antibacterial peptide having broad-spectrum bactericidal activity and use thereof
<160> 3
<170> SIPOSequenceListing 1.0
<210> 1
<211> 23
<212> PRT
<213> Artificial sequence (Artificial Sequence)
<400> 1
Tyr Phe Pro Pro Ala Lys Arg Leu Leu Asn Trp Ala Lys Lys Lys Val
1 5 10 15
Gly Ile Lys Lys Lys Lys Lys
20
<210> 2
<211> 23
<212> PRT
<213> Artificial sequence (Artificial Sequence)
<400> 2
Glu Lys Lys Pro Trp Ala Arg Leu Arg Phe Lys Phe Lys Leu Leu Lys
1 5 10 15
Gly Leu Ala Lys Lys Met Lys
20
<210> 3
<211> 15
<212> PRT
<213> Artificial sequence (Artificial Sequence)
<400> 3
Leu Lys Lys Leu Ala Gly Lys Ile Tyr Arg Val Leu Ala Lys Leu
1 5 10 15

Claims (2)

1. An application of the antibacterial peptide AMP-20 in preparing the antibacterial medicines of cryptococcus neoformans, candida albicans, drug-resistant candida tropicalis or escherichia coli, is characterized in that the amino acid sequence of the antibacterial peptide AMP-20 is shown in SEQ ID NO: 1.
2. The use according to claim 1, wherein the antimicrobial peptide has a minimum antimicrobial concentration of 2-16 μg/mL against cryptococcus neoformans.
CN202210392287.1A 2022-04-14 2022-04-14 Antibacterial peptide with broad-spectrum bactericidal activity and application thereof Active CN114773437B (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202410090896.0A CN117903254A (en) 2022-04-14 2022-04-14 Antibacterial peptide AMP-32 with broad-spectrum bactericidal activity and application thereof
CN202410090897.5A CN117886895A (en) 2022-04-14 2022-04-14 Antibacterial peptide AMP-29 with broad-spectrum bactericidal activity and application thereof
CN202210392287.1A CN114773437B (en) 2022-04-14 2022-04-14 Antibacterial peptide with broad-spectrum bactericidal activity and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210392287.1A CN114773437B (en) 2022-04-14 2022-04-14 Antibacterial peptide with broad-spectrum bactericidal activity and application thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202410090897.5A Division CN117886895A (en) 2022-04-14 2022-04-14 Antibacterial peptide AMP-29 with broad-spectrum bactericidal activity and application thereof
CN202410090896.0A Division CN117903254A (en) 2022-04-14 2022-04-14 Antibacterial peptide AMP-32 with broad-spectrum bactericidal activity and application thereof

Publications (2)

Publication Number Publication Date
CN114773437A CN114773437A (en) 2022-07-22
CN114773437B true CN114773437B (en) 2024-02-23

Family

ID=82429047

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202410090896.0A Pending CN117903254A (en) 2022-04-14 2022-04-14 Antibacterial peptide AMP-32 with broad-spectrum bactericidal activity and application thereof
CN202410090897.5A Pending CN117886895A (en) 2022-04-14 2022-04-14 Antibacterial peptide AMP-29 with broad-spectrum bactericidal activity and application thereof
CN202210392287.1A Active CN114773437B (en) 2022-04-14 2022-04-14 Antibacterial peptide with broad-spectrum bactericidal activity and application thereof

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN202410090896.0A Pending CN117903254A (en) 2022-04-14 2022-04-14 Antibacterial peptide AMP-32 with broad-spectrum bactericidal activity and application thereof
CN202410090897.5A Pending CN117886895A (en) 2022-04-14 2022-04-14 Antibacterial peptide AMP-29 with broad-spectrum bactericidal activity and application thereof

Country Status (1)

Country Link
CN (3) CN117903254A (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013100721A1 (en) * 2011-12-30 2013-07-04 조선대학교산학협력단 Novel antibacterial and fungicidal peptide in which lysine and tryptophan residues are repeated four times, and use thereof
WO2016124143A1 (en) * 2015-02-06 2016-08-11 浙江大学 Antimicrobial peptide wy-21 and use thereof
CN107652359A (en) * 2017-10-19 2018-02-02 浙江大学 Antibacterial peptide KR 32 and application thereof
CN107827966A (en) * 2017-10-19 2018-03-23 浙江大学 Antibacterial peptide KR 22 and application thereof
CN111057134A (en) * 2019-12-17 2020-04-24 倪京满 Antibacterial peptides with broad-spectrum antibacterial activity, low toxicity and no induced drug resistance and application thereof
CN113045627A (en) * 2021-03-18 2021-06-29 中国药科大学 Antibacterial polypeptide SA-2 and preparation method and application thereof
CN113185577A (en) * 2021-04-09 2021-07-30 倪京满 Low-toxicity broad-spectrum antibacterial peptide with different charge arrangement modes and different charge types and application thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013100721A1 (en) * 2011-12-30 2013-07-04 조선대학교산학협력단 Novel antibacterial and fungicidal peptide in which lysine and tryptophan residues are repeated four times, and use thereof
WO2016124143A1 (en) * 2015-02-06 2016-08-11 浙江大学 Antimicrobial peptide wy-21 and use thereof
CN107652359A (en) * 2017-10-19 2018-02-02 浙江大学 Antibacterial peptide KR 32 and application thereof
CN107827966A (en) * 2017-10-19 2018-03-23 浙江大学 Antibacterial peptide KR 22 and application thereof
CN111057134A (en) * 2019-12-17 2020-04-24 倪京满 Antibacterial peptides with broad-spectrum antibacterial activity, low toxicity and no induced drug resistance and application thereof
CN113045627A (en) * 2021-03-18 2021-06-29 中国药科大学 Antibacterial polypeptide SA-2 and preparation method and application thereof
CN113185577A (en) * 2021-04-09 2021-07-30 倪京满 Low-toxicity broad-spectrum antibacterial peptide with different charge arrangement modes and different charge types and application thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Evolution of genes and genomes on the Drosophila phylogeny;Drosophila 12 Genomes Consortium;《Nature》;第450卷(第8期);第203-218页 *
Novel antimicrobial peptide DvAMP serves as a promising antifungal agent against Cryptococcus neoformans;Longbing Yang et al;《Bioorganic Chemistry》;第138卷;第1-16页 *

Also Published As

Publication number Publication date
CN117903254A (en) 2024-04-19
CN117886895A (en) 2024-04-16
CN114773437A (en) 2022-07-22

Similar Documents

Publication Publication Date Title
Ciociola et al. Natural and synthetic peptides with antifungal activity
Faruck et al. An overview of antifungal peptides derived from insect
Reddy et al. Antimicrobial peptides: premises and promises
Harris et al. Anionic antimicrobial peptides from eukaryotic organisms
Schröder Epithelial peptide antibiotics
Tossi et al. Molecular diversity in gene-encoded, cationic antimicrobial polypeptides
Matejuk et al. Peptide-based antifungal therapies against emerging infections
Jang et al. Antifungal activity of synthetic peptide derived from halocidin, antimicrobial peptide from the tunicate, Halocynthia aurantium
Luisa Mangoni et al. Naturally occurring peptides from Rana temporaria: Antimicrobial properties and more
Zeng et al. Functional characterization of a novel lipopolysaccharide-binding antimicrobial and anti-inflammatory peptide in vitro and in vivo
Amiche et al. Dermaseptins as models for the elucidation of membrane-acting helical amphipathic antimicrobial peptides
JP4310107B2 (en) Short peptides having biological activity and methods of using the peptides
Conlon et al. The alyteserins: two families of antimicrobial peptides from the skin secretions of the midwife toad Alytes obstetricans (Alytidae)
Lee et al. Design of novel peptide analogs with potent fungicidal activity, based on PMAP-23 antimicrobial peptide isolated from porcine myeloid
Tomasinsig et al. Comparative activity and mechanism of action of three types of bovine antimicrobial peptides against pathogenic Prototheca spp.
Lu et al. Isolation, characterization and anti-cancer activity of SK84, a novel glycine-rich antimicrobial peptide from Drosophila virilis
Zhao et al. Research and application progress of insect antimicrobial peptides on food industry
KR101062975B1 (en) Antibiotic Peptide Derivatives Designed from Proteathiamycin Antibiotic Peptides
Liu et al. A novel amphibian antimicrobial peptide, phylloseptin-PV1, exhibits effective anti-staphylococcal activity without inducing either hepatic or renal toxicity in mice
Dawson et al. Cathelicidin peptide SMAP‐29: comprehensive review of its properties and potential as a novel class of antibiotics
Lima et al. Prevention of hospital pathogen biofilm formation by antimicrobial peptide KWI18
CN114773437B (en) Antibacterial peptide with broad-spectrum bactericidal activity and application thereof
Lin et al. Discovery of a novel antimicrobial peptide, Temporin-pke, from the skin secretion of Pelophylax kl. esculentus, and evaluation of its structure-activity relationships
DE102014101663A1 (en) Synthetic artificial peptides with antimicrobial activity
King et al. Purification and characterization of antimicrobial peptides from the Caribbean frog, Leptodactylus validus (Anura: Leptodactylidae)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant